Introduction
- STEMI (ST-Elevation Myocardial Infarction) represents a critical emergency where timely intervention is crucial. Atorvastatin, a statin, has been investigated for its potential benefits when administered early during a STEMI.
- Early administration of atorvastatin may have pleiotropic effects beyond cholesterol lowering. Potential benefits include stabilization of atherosclerotic plaques, reduction of inflammation, and improved endothelial function.
- Guidelines recommend initiating high-intensity statin therapy as soon as possible in STEMI patients.
- This pharmacy pearl summarizes the pharmacology and evidence supporting the use of atorvastatin in this setting.
Pharmacology
| Atorvastatin | Rosuvastatin | |
| Dose | 80 mg orally once daily | 40 mg orally once daily |
| Administration | Oral | Oral |
| PK/PD | Onset: 3-5 days for LDL reduction; Peak effect: 2-4 weeks | Onset: 3-5 days for LDL reduction; Peak effect: 2-4 weeks |
| Adverse Effects | Myopathy, elevated liver enzymes, gastrointestinal symptoms | Myopathy, elevated liver enzymes, gastrointestinal symptoms |
| Drug Interactions and warnings | CYP3A4 inhibitors/inducers can affect levels; avoid in active liver disease | Minimal CYP interactions; avoid in active liver disease |
| Compatibility | Compatible with most cardiovascular drugs, monitor for interactions with CYP3A4 inhibitors | Compatible with most cardiovascular drugs, minimal interactions |
| Comments | High-intensity statin recommended post-STEMI to reduce recurrence risk | High-intensity statin alternative to atorvastatin |
Overview of Evidence
| Author, Year | Design/Sample Size | Intervention & Comparison | Outcome | |
| Schwartz, 2001 | Randomized Controlled Trial (n=3086) | Atorvastatin (80 mg/day) vs. placebo initiated 2496 hours after acute coronary syndrome | Atorvastatin reduced recurrent symptomatic ischemia requiring rehospitalization (6.2% vs 8.4%; RR, 0.74; P=0.02) | |
| Li, 2012 | Randomized Controlled Trial (n=161) | High-dose atorvastatin (80 mg) vs. placebo in patients with STEMI undergoing PCI | High-dose atorvastatin significantly reduced the incidence of contrast-induced nephropathy (2.6% vs 15.7%; P=0.01) | |
| Liu, 2013 | Randomized Controlled Trial (n=102) | Loading dose of atorvastatin (80 mg) before PCI vs. no loading dose | Loading dose of atorvastatin reduced high-sensitivity C-reactive protein, B-type natriuretic peptide, and matrix metalloproteinase type 9, indicating reduced inflammation and improved cardiac function (P<0.05) | |
| Xu, 2016 | Randomized Controlled Trial (n=120) | Intensive atorvastatin (40 mg) vs. standard atorvastatin (20 mg) in STEMI patients undergoing PCI | Intensive atorvastatin significantly reduced serum endothelin-1 levels and ADP-induced platelet clot strength, improving endothelial function and platelet inhibition (P<0.05) | |
| Kim, 2015 | Randomized Controlled Trial (n=67) | High-dose atorvastatin (80 mg) before PCI vs. low-dose atorvastatin (10 mg) | No significant reduction in myocardial damage; however, high-dose pretreatment is generally considered safe and well-tolerated | |
| Gavazzoni, 2017 | Randomized Controlled Trial (n=52) | High-dose atorvastatin (80 mg) vs. moderate dose (20 mg) in STEMI patients | High-dose atorvastatin showed significant improvement in endothelial function (RH-PAT index 1.96±0.16 vs 1.72±0.19; P=0.002) and reduced levels of high-sensitivity CRP and IL6 (P<0.05) | |
| Liu, 2013 | Randomized Controlled Trial (n=102) | Loading dose of atorvastatin (80 mg) before PCI vs. no loading dose | Loading dose of atorvastatin significantly lowered inflammatory markers and improved left ventricular ejection fraction compared to no loading dose (P<0.05) | |
| Adel, 2022 | Randomized Controlled Trial (n=99) | High-dose rosuvastatin (40 mg) vs. high-dose atorvastatin (80 mg) before PCI in STEMI patients | Atorvastatin group had lower CTFC and better TIMI flow grade compared to control, and both statins improved microvascular myocardial perfusion (P<0.01) | |
| Chen, 2022 | Randomized Controlled Trial (n=98) | Enhanced-dose atorvastatin (40 mg before PCI, 40 mg/day post-PCI, 20 mg/day after 1 week) vs. standarddose atorvastatin (20 mg/day) | Enhanced-dose atorvastatin improved cardiac output, LVEF, TIMI blood flow classification, and reduced incidence of major adverse cardiac events (P<0.05) | |
Conclusions
- Efficacy: High-intensity atorvastatin (80 mg) initiated early in the ED for STEMI patients reduces the risk of subsequent cardiovascular events and mortality.
- Safety: Generally well-tolerated with a similar side effect profile to other statins, though monitoring for myopathy and liver enzyme elevations is necessary.
- Recommendation: Incorporating early administration of atorvastatin 80 mg for STEMI patients in the ED aligns with current guidelines and improves patient outcomes.
References
- Micromedex [Electronic version].Greenwood Village, CO: Truven Health Analytics. Retrieved July 1 2024, from http://www.micromedexsolutions.com/
- Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
- Liu H, Yang Y, Yang SL, et al. Administration of a loading dose of atorvastatin before emergency PCI reduces myocardial damage in patients with STEMI. Clin Ther. 2013;35(1):22-30.
- Li W, Fu X, Wang Y, et al. Beneficial effects of high-dose atorvastatin pretreatment on microvascular obstruction and left ventricular function in STEMI patients undergoing primary PCI. Cardiology. 2012;123(4):212-220.
- Kim EK, Hahn J, Song Y, et al. Effects of high-dose atorvastatin pretreatment on microvascular obstruction in STEMI patients undergoing primary PCI. J Korean Med Sci. 2015;30(4):435-441.
- Xu X, Liu Y, Li K, et al. Intensive atorvastatin improves endothelial function and reduces inflammation in STEMI patients undergoing primary PCI. Int J Cardiol. 2016;220:616-621.
- Gavazzoni M, Lombardi CM, Vizzardi E, et al. Role of early high-dose atorvastatin loading in STsegment elevation myocardial infarction: real-life experience. J Cardiovasc Med (Hagerstown). 2017;18(6):406-411.
- Adel EM, Elberry A, Abdel Aziz A, Ibrahim MA, Abdelaal FA. Comparison of the treatment efficacy of rosuvastatin versus atorvastatin in preventing microvascular obstruction in patients undergoing primary PCI for STEMI. J Clin Med. 2022;11(17):5142.
- Chen Y, Zhang J, Huo Y, et al. Effects of atorvastatin on coronary microvascular function in STEMI patients undergoing primary PCI: a randomized controlled trial. J Am Coll Cardiol. 2022;79(9):901911.